+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 75Years
All Genders
ID07111273

Predicting One-Year Relapse or Treatment Needs in Biologic-Naive Ulcerative Colitis Using Early Changes in Stool Biomarkers

Led by Qilu Hospital of Shandong University · Updated on 2026-07-28

100

Participants Needed

1

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

This research investigates whether early changes in stool biomarkers, specifically quantitative fecal immunochemical test qFIT and fecal calprotectin FC, can predict clinical relapse or the need for treatment escalation in patients with active ulcerative colitis UC who have not previously received biologic therapies. The study is a prospective, observational cohort conducted across multiple centers in China and aims to improve prediction of disease outcomes within one year. It also explores secondary goals including prediction at 4 weeks, development of dynamic models, health economic evaluations, and baseline factors influencing early biomarker response. Participants are biologic-naive UC patients with confirmed active disease Mayo Endoscopic Subscore 2 starting conventional treatments such as mesalazine or corticosteroids. Stool samples to measure qFIT and FC levels are collected at baseline Week 0, Week 2, and Week 4. Based on Week 2 biomarker changes, patients are categorized as rapid responders significant decrease or normalization or slownon-responders less decrease. The study observes patients under routine care with biomarker results blinded to clinicians and patients until study completion. Participants will be followed for 52 weeks to monitor for clinical relapse or escalation to biologicJAK inhibitor treatments, defined by specific clinical criteria. The study collects data on remission rates, mucosal healing, and biomarker diagnostic performance. Stool samples and clinical assessments occur at specified weeks, with researchers measuring time to relapse, corticosteroid-free remission, and predictive accuracy of biomarker changes. Safety and treatment adherence are monitored as part of standard care during the study period.

CONDITIONS

Brief Title

DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis

Research Team

Y

Yan Zhang, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here